

**WEST****Freeform Search****Database:**

US Patents Full-Text Database  
US Pre-Grant Publication Full-Text Database  
JPO Abstracts Database  
EPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

**Term:**

L19 with 115 with 19

**Display:**  **Documents in Display Format:**  **Starting with Number** **Generate:** ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show S Numbers

Edit S Numbers

Preferences

Cases

**Search History****DATE:** Friday, July 11, 2003 [Printable Copy](#) [Create Case](#)

**WEST**

Generate Collection

Print

L18: Entry 1 of 5

File: PGPB

Sep 5, 2002

DOCUMENT-IDENTIFIER: US 20020122819 A1

TITLE: Novel liposome complexes for increased systemic delivery

Detail Description Paragraph (35):

[0064] The sandwich liposome complexes of the present invention may be used to make effective artificial viruses. Because the outside of the sandwich liposome complexes is substantially free of biologically active agents, targeting ligands may be placed on the outside after sandwich liposome formation, without compromising the effect of the targeting ligand or the ability of the biologically active agents to be delivered and expressed. This may enable delivery to specific organs and tissues. The size of the sandwich liposome complexes responsible for efficient delivery, 200 to 450 nm (see also Table 1), is preferred for the addition of targeting ligands. Our experiments demonstrate the usefulness of this approach (See Example 9, FIG. 7).

**WEST**

Generate Collection

Print

L18: Entry 3 of 5

File: USPT

Jul 30, 2002

DOCUMENT-IDENTIFIER: US 6426086 B1

TITLE: pH-sensitive, serum-stable liposomes

Detailed Description Text (128):

Drug-to-lipid ratios were determined both before and after polymer addition to see if adding the polymer resulted in any destabilization of the liposomes. Following addition of the polymer, liposomes lost approximately 5% of their total doxorubicin, indicating only a minor disruption of the liposome resulted from polymer introduction. The size of the liposomes was similar--73.9 vs 83.7--for the two preparations. The folate-PEG-DSPF, containing composition is likely closer to the 74 nm shown for the non-targeted liposomes, but was weighted slightly higher due to a small amount of contamination with larger particles. This size is well within the optimal size range for liposome use in vivo. Liposomes are taken up by macrophages of the RES in a fashion dependent on the size of the liposomes; smaller liposomes are taken up less readily than large liposomes.

**WEST****End of Result Set**

Generate Collection

Print

L18: Entry 5 of 5

File: USPT

Feb 29, 2000

DOCUMENT-IDENTIFIER: US 6030942 A

TITLE: Peptides peptide analogs peptidomimetics and other small molecules useful for inhibiting the activity of ribonucleotide reductase

Detailed Description Text (391):

Leamon et al. (1991, Proc. Natl. Acad. Sci. USA 88:5572-5576; Leamon et al., 1993, Biochem. J. 291:855-860; Leamon et al., 1993, J. Biol. Chem. 268 (33):24847-24854) have demonstrated that proteins covalently attached to folic acid are taken up into cells by folate binding protein (FBP) mediated endocytosis, and have used this approach to introduce toxic proteins such as momordin, a ribosome-inactivating protein into cells, thereby killing them. Because FBP is vastly overexpressed on certain malignant cell surfaces, including those of Hela and Caco-2 cells (Leamon et al., 1994, J. Drug Target 2:101-112; Weitman et al., 1992, Cancer Res. 52:3396-3401), this approach can in some cases permit selective destruction of malignant cells. More recently, Low and colleagues have extended this approach by demonstrating that liposomes (66 nm) conjugated to folate via a polyethylene glycol (PEG) spacer (M.sub.r .about.3250) can be used to deliver materials contained within the liposome, such as antisense oligonucleotides and doxorubicin, into cancer cells (Lee et al., 1994, J. Biol. Chem. 269:3198-3204; Lee et al., 1995, Biochim. Biophys. Acta 1233, 134-144; Wang et al., 1995, Proc. Natl. Acad. Sci. USA 92:3318-3322).

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<u>L20</u>	L19 with l15 with l9	4	<u>L20</u>
<u>L19</u>	directly	1777422	<u>L19</u>
<u>L18</u>	l15 with l9 with l11	5	<u>L18</u>
<u>L17</u>	L16 and l13	20	<u>L17</u>
<u>L16</u>	L15 same l14	20	<u>L16</u>
<u>L15</u>	targeting ligand or folate or transferrin	11724	<u>L15</u>
<u>L14</u>	l13 same l9	1136	<u>L14</u>
<u>L13</u>	spherical or accentric	281404	<u>L13</u>
<u>L12</u>	L11 with l9	1633	<u>L12</u>
<u>L11</u>	nm	323164	<u>L11</u>
<u>L10</u>	intravenous or systemic	119302	<u>L10</u>
<u>L9</u>	liposome or cationic lipid or polyplex	40451	<u>L9</u>
<u>L8</u>	intact vector with l1	1	<u>L8</u>
<u>L7</u>	L6 and l5	23	<u>L7</u>
<u>L6</u>	gene therapy	29969	<u>L6</u>
<u>L5</u>	L4 with l3	68	<u>L5</u>
<u>L4</u>	dna or nucleic or plasmid	197612	<u>L4</u>
<u>L3</u>	l2 with L1	2007	<u>L3</u>
<u>L2</u>	intact or supercoiled	110023	<u>L2</u>
<u>L1</u>	microparticle or microsphere or polymer	1495484	<u>L1</u>

END OF SEARCH HISTORY